In MCL, FoxO1 serves as a master factor driving MCL‐lineage‐specific transcription programs that ensure the survival and proliferation of lymphoma cells (Fig. 5) [9], and a novel FoxO1 inhibitor has been tested in this context (cpd10) [123]. Here, FOXO1 is linked to mantle cell lymphoma.